Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) EBIT Margin (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed EBIT Margin for 15 consecutive years, with 2.22% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 1167.0% to 2.22% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5.88% through Dec 2025, down 1440.0% year-over-year, with the annual reading at 5.88% for FY2025, 1440.0% down from the prior year.
  • EBIT Margin hit 2.22% in Q4 2025 for Corcept Therapeutics, down from 4.92% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 37.69% in Q3 2021 to a low of 2.17% in Q1 2025.
  • Historically, EBIT Margin has averaged 21.93% across 5 years, with a median of 24.05% in 2021.
  • Biggest five-year swings in EBIT Margin: soared 906bps in 2021 and later tumbled -2061bps in 2025.
  • Year by year, EBIT Margin stood at 37.1% in 2021, then plummeted by -41bps to 21.83% in 2022, then increased by 7bps to 23.39% in 2023, then plummeted by -41bps to 13.89% in 2024, then plummeted by -84bps to 2.22% in 2025.
  • Business Quant data shows EBIT Margin for CORT at 2.22% in Q4 2025, 4.92% in Q3 2025, and 13.72% in Q2 2025.